Education
About Us
Working with TipRanks
Follow Us
Capricor Therapeutics (CAPR)
NASDAQ:CAPR
CAPR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.52 - $23.40
Previous CloseN/A
Volume187.65K
Average Volume (3M)1.45M
Market Cap
$584.74M
Enterprise Value$423.30M
Total Cash (Recent Filing)$4.26M
Total Debt (Recent Filing)$3.38M
Price to Earnings (P/E)―
Beta1.48
Next Earnings
May 08, 2025EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.20
Shares Outstanding45,469,910
10 Day Avg. Volume1,502,655
30 Day Avg. Volume1,450,290
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)25.17
Price to Cash Flow (P/CF)-12.60
P/FCF Ratio0.00
Enterprise Value/Market Cap0.72
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit17.56
Enterprise Value/Ebitda-12.17
Forecast
1Y Price Target
$43.60Price Target Upside228.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceCapricor announced financial results that exceeded estimates with a lower-than-expected loss, ending the quarter with $151.5 million in cash.
International ExpansionA term sheet with Nippon Shinyaku for deramiocel's marketing, sales, and distribution in Europe signifies potential growth opportunities in international markets.
Regulatory MilestonesThe FDA accepted deramiocel's BLA for DMD cardiomyopathy and granted it Priority Review, which is a significant step forward for Capricor.
Bears Say
Market CompetitionDifferentiated durability, efficacy, and safety could be keys to success following a potential approval and market entrance.
Operational ChallengesCapricor is expanding its manufacturing capacity to produce deramiocel for approximately 2,000-3,000 patients, with a new facility expected to be operational by mid-2026.
---
Ownership Overview
16.88% Insiders
6.04% Mutual Funds
15.64% Other Institutional Investors
49.88% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
CAPR FAQ
What was Capricor Therapeutics’s price range in the past 12 months?
Capricor Therapeutics lowest stock price was $3.52 and its highest was $23.40 in the past 12 months.
What is Capricor Therapeutics’s market cap?
Capricor Therapeutics’s market cap is $584.74M.
When is Capricor Therapeutics’s upcoming earnings report date?
Capricor Therapeutics’s upcoming earnings report date is May 08, 2025 which is in 43 days.
How were Capricor Therapeutics’s earnings last quarter?
Capricor Therapeutics released its earnings results on Mar 19, 2025. The company reported -$0.16 earnings per share for the quarter, beating the consensus estimate of -$0.17 by $0.01.
Is Capricor Therapeutics overvalued?
According to Wall Street analysts Capricor Therapeutics’s price is currently Undervalued.
Does Capricor Therapeutics pay dividends?
Capricor Therapeutics does not currently pay dividends.
What is Capricor Therapeutics’s EPS estimate?
Capricor Therapeutics’s EPS estimate is -0.31.
How many shares outstanding does Capricor Therapeutics have?
Capricor Therapeutics has 45,469,910 shares outstanding.
What happened to Capricor Therapeutics’s price movement after its last earnings report?
Capricor Therapeutics reported an EPS of -$0.16 in its last earnings report, beating expectations of -$0.17. Following the earnings report the stock price went up 17.512%.
Which hedge fund is a major shareholder of Capricor Therapeutics?
Currently, no hedge funds are holding shares in CAPR
---
Capricor Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$43.60 (228.31% Upside)
$43.60 (228.31% Upside)
Blogger Sentiment
Bullish
CAPR Sentiment 66%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 2.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.6%
Last 30 Days ▲ 1.0%
Last 30 Days ▲ 1.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
108.15%
12-Months-Change
Fundamentals
Return on Equity
-48.16%
Trailing 12-Months
Asset Growth
190.26%
Trailing 12-Months
Company Description
Capricor Therapeutics
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.
---
CAPR Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlights significant progress towards Deramiocel's FDA approval and commercialization, backed by strong safety and efficacy data, a robust manufacturing strategy, and a solid financial position. However, increased operating expenses and a larger net loss present some financial challenges. The pending European agreement also remains a point of uncertainty.Read More>---
CAPR Stock 12 Month Forecast
Average Price Target
$43.60
▲(228.31% Upside)
Technical Analysis
Mesoblast
―
Sorrento Therapeutics
―
CryoPort
―
Brainstorm Cell Therapeutics
―
Adaptimmune Therapeutics
―
Best Analysts Covering CAPR
1 Year
1 Year Success Rate
11/15 ratings generated profit
1 Year Average Return
+155.54%
reiterated a buy rating 6 days ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 73.33% of your transactions generating a profit, with an average return of +155.54% per trade.
---